The combination of the selective inhibitor of nuclear export (SINE), selinexor, and weekly paclitaxel is tolerable.
•Most common toxicites from selinexor and paclitaxel included bone marrow suppression, nausea, and fatigue.
•Selinexor and weekly paclitaxel yielded clinical benefit in heavily pre-treated platinum-resistant ovarian cancer.
AbstractObjectiveSelinexor is a first-in-class, oral selective inhibitor of nuclear export (SINE) compound which blocks Exportin-1 (XPO1). Our objective was to determine maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of selinexor and weekly paclitaxel.
MethodsThis was an open label, single-center, multi-arm phase 1b study utilizing a “3 + 3” design and a “basket-type” expansion in recurrent solid tumors. Selinexor (60 mg or 80 mg twice weekly orally) and weekly paclitaxel (80 mg IV 2 week on, 1 week off) were one of 13 parallel arms. Efficacy was evaluated using RECIST version 1.1.
ResultsAll 35 patients treated were evaluable for toxicity and 31 (88%) were evaluable for response. Patient diagnoses included platinum-resistant/refractory ovarian (n = 28), breast (n = 4), prostate (n = 2), and cervical (n = 1) cancer. Patients had a median of four prior therapies (range 1–10), and 47% had a prior taxane in the recurrent setting. There were no DLTs and 60 mg was chosen as the RP2D due to long-term tolerability. Ninety-seven percent of patients had at least one treatment-emergent adverse event (TEAE), and the most common grade ≥ 3 TEAE were neutropenia (46%), anemia (31%), and nausea (21%). Among 24 evaluable patients with ovarian cancer, response rate was 17%, CBR was 58%, and median PFS was 6.8 months (95% CI 3.7, not reached (NR)).
ConclusionsOral selinexor in combination with weekly paclitaxel demonstrated promising clinical activity with manageable toxicity. This combination should be considered for further exploration in a randomized study, especially in ovarian malignancies.
KeywordsSelinexor
Paclitaxel
Metastatic solid tumors
Ovarian cancer
Selective inhibitor of nuclear export (SINE)
View full text© 2022 Elsevier Inc. All rights reserved.
留言 (0)